{"id":"rvsv-g-zebov-gp","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rVSV∆G-ZEBOV-GP is a live attenuated viral vector vaccine in which the glycoprotein gene of vesicular stomatitis virus (VSV) is replaced with the glycoprotein gene from Zaire ebolavirus (ZEBOV). This allows the vaccine to stimulate both cellular and humoral immune responses against Ebola virus without causing VSV disease. The vaccine triggers production of antibodies and T-cell responses specific to Ebola glycoprotein, providing protection against Ebola virus infection.","oneSentence":"A recombinant vesicular stomatitis virus vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and attack Ebola virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:28.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ebola virus disease prevention (marketed as Ervebo)"}]},"trialDetails":[{"nctId":"NCT06100913","phase":"PHASE2","title":"Immunology of Ebola Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2024-08-06","conditions":"Ebola Virus Disease","enrollment":30},{"nctId":"NCT06841614","phase":"PHASE3","title":"EBOla Post-Exposure Prophylaxis","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2026-09","conditions":"Ebola Virus Disease","enrollment":160},{"nctId":"NCT02788227","phase":"PHASE2","title":"Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-14","conditions":"Healthy Volunteers","enrollment":99},{"nctId":"NCT05959421","phase":"PHASE3","title":"Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure","status":"NOT_YET_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2026-06","conditions":"Ebola Vaccine","enrollment":70},{"nctId":"NCT05178901","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2022-01-10","conditions":"Nipah Virus Infection","enrollment":60},{"nctId":"NCT06587503","phase":"PHASE4","title":"Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2024-10","conditions":"Ebola Virus Disease, COVID-19","enrollment":72},{"nctId":"NCT04822376","phase":"PHASE2","title":"Prophylaxis Vaccine Antibodies Ebola","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-10-17","conditions":"Ebola Virus Disease","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ervebo"],"phase":"marketed","status":"active","brandName":"rVSV∆G-ZEBOV-GP","genericName":"rVSV∆G-ZEBOV-GP","companyName":"University of Birmingham","companyId":"university-of-birmingham","modality":"Biologic","firstApprovalDate":"","aiSummary":"A recombinant vesicular stomatitis virus vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and attack Ebola virus. Used for Ebola virus disease prevention (marketed as Ervebo).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}